Leaflet IRBEZYD COMBI 300mg / 12.5mg film-coated tablets


Indicated for: hypertension

Substance: irbesartan + hydrochlorothiazide (angiotensin II receptor blocker + diuretic)

ATC: C09DA04 (Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs) and diuretics)

The combination of irbesartan and hydrochlorothiazide is used to treat essential hypertension in patients who do not respond adequately to monotherapy. Irbesartan is an angiotensin II receptor antagonist that helps relax blood vessels, while hydrochlorothiazide is a diuretic that reduces fluid volume in the body, thereby lowering blood pressure.

The medication is taken orally, usually once daily, as directed by a doctor.

Side effects may include dizziness, fatigue, nausea, or electrolyte imbalances. In rare cases, severe allergic reactions or kidney dysfunction may occur.

Patients should inform their doctor about any other medications they are taking and strictly follow the treatment regimen. Pregnant or breastfeeding women should not use this medication.

General data about IRBEZYD COMBI 300mg / 12.5mg

  • Substance: irbesartan + hydrochlorothiazide
  • Date of last drug list: 01-10-2013
  • Commercial code: W57162001
  • Concentration: 300mg / 12.5mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 28
  • Product type: generic
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Pharmaceutical forms available for irbesartan + hydrochlorothiazide

Concentrations available for irbesartan + hydrochlorothiazide

  • 150mg/12.5mg
  • 300mg/12.5mg
  • 300mg/25mg